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Midregional Pro-Atrial Natriuretic Peptide and
Outcome in Patients With Acute Ischemic Stroke
Mira Katan, MD,*† Felix Fluri, MD,† Philipp Schuetz, MD,* Nils G. Morgenthaler, MD, PHD,‡
Christian Zweifel, MD,§ Roland Bingisser, MD, Ludwig Kappos, MD,† Andreas Steck, MD,†
Stefan T. Engelter, MD,† Beat Müller, MD,*¶ Mirjam Christ-Crain, MD*
Basel and Aarau, Switzerland; and Hennigsdorf/Berlin, Germany
Objectives The purpose of this study was to examine the prognostic value of midregional pro-atrial natriuretic peptide (MR-
proANP) in patients with acute ischemic stroke.
Background The rapid and reliable estimation of prognosis in acute ischemic stroke is pivotal to optimize clinical care. MR-
proANP, a recently described, stable fragment of the ANP precursor hormone, may be useful in this setting.
Methods In a prospective observational study, we measured MR-proANP on admission in plasma of 362 consecutive pa-
tients presenting with acute ischemic stroke. The prognostic value of MR-proANP to predict mortality within 90
days and functional outcome (defined as a modified Rankin Scale of 2 or 3) was evaluated and compared
with the National Institutes of Health Stroke Scale (NIHSS) score.
Results The discriminatory accuracy, calculated with the area under the curve (AUC) of the receiver operating character-
istics curve, of MR-proANP to predict death was comparable to the NIHSS (AUC: 0.86 [95% confidence interval
(CI): 0.82 to 0.90] and 0.85 [95% CI: 0.81 to 0.89; p  0.7]). Combined, the accuracy significantly improved
(0.92 [95% CI: 0.88 to 0.96; p  0.01]). The AUC of MR-proANP to predict functional outcome was 0.70 (95%
CI: 0.65 to 0.75), similar to the NIHSS (0.75 [95% CI: 0.70 to 0.80]; p  0.16). The prognostic value of MR-
proANP for both outcomes was independent of the NIHSS. Higher MR-proANP concentrations were found in
stroke of cardioembolic etiology.
Conclusions MR-proANP is a prognostic marker in the acute phase of stroke, improving the discriminatory value of the
NIHSS, independently predicting post-stroke mortality and functional outcome. (The “COSMOS”-Study [Copeptin
in Osmoregulation and Stress Assessment]; NCT00390962) (J Am Coll Cardiol 2010;56:1045–53) © 2010 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.071i
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ttroke is the third leading cause of death and the primary
ause of long-term disability worldwide (1). The direct and
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ccepted February 25, 2010.ndirect cost of stroke amounted to $65.5 billion in 2008
2). Each year, over 5 million people die as a consequence of
troke, and at least 1 in 6 patients who survives a stroke will
uffer another stroke within 5 years (3). An early risk
ssessment with estimate of the severity of disease and
rognosis could facilitate optimized care and allocation of
ealth care resources (4). Thus, there is the need to develop a
redible evidence base of prognostic information for out-
See page 1054
omes that are meaningful to patients, including mortality
nd level of independency. In this context, prognostic
arkers available during the initial phase after acute stroke
ould aid in the timely estimation of disease severity,
unctional outcome, and mortality.
A-type natriuretic peptide (ANP) is a family member of
he natriuretic peptides. Its physiological role is mainly the
egulation of blood pressure ascribed to its natriuretic,
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ANP emerged as reliable prog-
nostic marker for congestive
heart failure and risk of cardio-
vascular events and death (5,6).
In the acute phase of ischemic
stroke, levels of ANP have been
reported to be elevated (7) and to
predict mortality (8). Immuno-
histochemical studies suggest
that cerebral ischemia directly in-
duces ANP secretion in brain
tissue (9,10). Interestingly, indi-
viduals with a homozygous geno-
type for the ANP stop codon
mutation have an increased risk
of ischemic stroke (11). Thus,
ANP is likely to play a role in the
hemodynamic regulation during
the acute phase of ischemic
stroke.
Midregional pro-ANP (MR-
proANP) derives from the pre-
cursor hormone of ANP. MR-
proANP is released in an equimolar
ratio to ANP. The present assay
for MR-proANP was designed
to detect the midregion of the
prohormone, which is more sta-
ble than the N- or C-terminal
part of the precursor (12). Other
proANP assays may underesti-
mate the release of the precursor
ue to an early degradation of crucial epitopes at the
xtreme ends of the molecule. The midregional fragment of
roANP is also more stable in blood ex vivo, which renders
t generally more applicable in clinical practice (13). Frag-
ents of natriuretic prohormones (i.e., MR-proANP and
ro-brain natriuretic peptide [proBNP], respectively) pre-
ict poor outcomes in patients after acute myocardial
nfarction and in patients with heart failure (14–18). We
ypothesize that MR-proANP, measured in the acute phase
fter an ischemic stroke, is a good prognostic marker for
unctional outcome and mortality within 90 days.
ethods
tudy design and setting. We conducted a prospective
ohort study at the University Hospital Basel, Basel, Swit-
erland. From November 2006 to November 2007, consec-
tive patients presenting with an acute ischemic cerebrovas-
ular event were included. The primary end point of this
tudy was to evaluate prognostic biomarkers, particularly the
rginine vasopressin (AVP) precursor (copeptin) and the
recursor hormone of ANP (MR-proANP) to predict
Abbreviations
and Acronyms
AF  atrial fibrillation
ANP  A-type natriuretic
peptide
AUC  area under the
curve
AVP  arginine vasopressin
CE  cardioembolism
CI  confidence interval
IQR  interquartile range
LACS  lacunar syndrome
MR-proANP  midregional
pro-atrial natriuretic
peptide
mRS  modified Rankin
Scale
NIHSS  National
Institutes of Health Stroke
Scale
OR  odds ratio
PACS  partial anterior
circulation syndrome
POCS  posterior
circulation syndrome
proBNP  pro-brain
natriuretic peptide
ROC  receiver-operating
characteristic curve
TACS  total anterior
circulation syndromeutcome in ischemic stroke. A complete description of Wopeptin and stroke outcome has been reported previously
19). In brief, after approval from the Ethics Committee of
he University Hospital Basel was received, written in-
ormed consent was obtained from study participants or, if
ot feasible, from next of kin. A total of 605 consecutive
atients with a suspicion of stroke within 72 h before
dmission at the emergency department were examined.
For the purpose of this study, we evaluated all patients
ith the final diagnosis of ischemic stroke (n  362),
onfirmed by computed tomography and/or magnetic res-
nance imaging on admission. The other 243 patients had
ither transient ischemic attack, intracerebral hemorrhage,
r other final diagnoses and were excluded from the final
nalysis. Neurological deficits were assessed using the Na-
ional Institutes of Health Stroke Scale (NIHSS) prospec-
ively on admission in all patients. Blood samples were
ollected within 0 to 3 h (n  78), 3 to 12 h (n  189), 12
o 24 h (n  55), and 24 to 72 h (n  40) from symptom
nset. The clinical stroke syndrome was determined by
pplying the criteria of the Oxfordshire Community Stroke
roject; that is, total anterior circulation syndrome (TACS),
artial anterior circulation syndrome (PACS), lacunar syn-
rome (LACS), and posterior circulation syndrome
POCS) (20). Stroke etiology was determined according to
he criteria of the TOAST (Trial of Org 10172 in Acute
troke Treatment) classification (21), which distinguishes
arge artery arteriosclerosis, cardioembolism, small artery
cclusion, other etiology, and undetermined etiology. At
ischarge from the hospital, each patient received an etio-
ogic diagnosis of stroke.
ollow-up and end points. All patients underwent a
tructured telephone interview after 90 days in order to
dentify occurrence and timing of mortality of any cause and
unctional outcome. Ninety-day outcome was measured by
he modified Rankin Scale (mRS), and a favorable outcome
as defined as a mRS score of 0 to 2.
ssays. Blood was obtained from a venous catheter. Re-
ults of the routine blood analyses were recorded. Plasma
as frozen at 70°C. MR-proANP was detected in plasma
rom all patients with a new sandwich immunoassay
BRAHMS AG, Hennigsdorf/Berlin, Germany), as de-
cribed in detail elsewhere (13). In brief, the lower detection
imit of the assay is 6.0 pmol/l. The intra-assay coefficient of
ariation was 10% for samples containing 23 to 3,000
mol/l MR-proANP and 20% for samples containing 18 to
2.8 pmol/l. The interassay coefficient of variation was 10%
t the concentration of 65 pmol/l MR-proANP and 20% at
concentration of 18 pmol/l MR-proANP. In 325 healthy
ndividuals, the range of MR-proANP concentrations was
.6 to 313 pmol/l. The median was 45 pmol/l (95%
onfidence interval [CI]: 43.0 to 49.1 pmol/l) (13).
tatistical analysis. Discrete variables are expressed as
ounts (percentage), and continuous variables as medians
nd interquartile ranges (IQRs). Two-group comparison of
ot normally distributed data was performed using Mann-hitney U test and a Kruskal-Wallis 1-way analysis of
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September 21, 2010:1045–53 MR-proANP Predicts Outcome in Stroke Patientsariance was used for multigroup comparisons. First, the
elation of MR-proANP with outcomes (i.e., death and
unctional outcome in stroke patients) was assessed using
ogistic regression models. All baseline parameters were
nalyzed. Thereby, common logarithmic transformation
i.e., base 10) was performed to obtain normal distribution
or skewed variables (i.e., MR-proANP concentrations) as
he resulting model yielded a smaller Akaike Information
riterion, which was chosen to compare the results. We
sed crude models and only report odds ratios (ORs) of
iological important or significant predictors in our tables.
ultivariate models were adjusted for 3 biologically impor-
ant outcome predictors for the end point mortality (n 44)
o avoid overfitting. For the end point functional outcome,
e adjusted for all significant predictors, and then for the 4
ain predictors. Note that the OR corresponds to an
ncrease by 1 U in the explanatory variable. In terms of
og-transformed MR-proANP values, the OR corresponds
o a 10-fold increase.
Second, we compared the overall discriminatory ability of
ifferent predictors by calculating receiver-operating char-
cteristic curve (ROC) analysis with the method by DeLong
t al. (22). Thereby, the area under the ROC (AUC) is a
ummary measure over criteria and cut-point choices. The
UC summary equals the probability that the underlying
lassifier will score a randomly drawn positive sample higher
han a randomly drawn negative sample. To test whether
he MR-proANP level improves the performance of the
IHSS score, we compared ROCs of the logistic regression
odel combining the NIHSS score with MR-proANP with
ROC limited to the NIHSS. We also compared ROCs of
R-proANP and copeptin, which is a recently published
rognostic biomarker in acute ischemic stroke.
Finally, to study the ability of MR-proANP to predict
ortality, we calculated Kaplan-Meier survival curves and
tratified patients by quartiles. All testing was 2-tailed, and
values 0.05 were considered to indicate statistical
ignificance. All calculations were performed using STATA
ersion 9.2 (Stata Corp, College Station, Texas).
esults
aseline characteristics. Of the 362 consecutively en-
olled patients with an ischemic stroke, 359 patients
ompleted the 90-day follow-up and were analyzed; 2
atients were lost to follow-up, and 1 patient withdrew
nformed consent.
The median age of patients was 75 years (IQR 63 to 83
ears), and 41% were women. Vital signs assessed on
dmission revealed a median systolic blood pressure of 160
m Hg (IQR 140 to 180 mm Hg) and a body temper-
ture of 37.0°C (IQR 36.5°C to 37.4°C). Regarding the
eurological deficits on admission, the median NIHSS was
points (IQR 2 to 10 points). A total of 275 patients (77%)
ad a history of hypertension, 93 (26%) had hypercholes-
erolemia, 71 (20%) had a history of diabetes mellitus, 124 a35%) were smokers, 75 (21%) were diagnosed with atrial
brillation (AF), 88 (25%) had a history of a previous
ascular event, 91 (25%) had coronary heart disease, and 54
15%) had a history of heart failure. According to the
xfordshire Community Stroke Project classification, 162
45%) had a PACS, 41 (11%) a TACS, 74 (21%) a LACS,
nd 83 (23%) a POCS. Baseline characteristics of the study
opulation are provided in Table 1.
Outcome evaluation of the stroke population after 90
ays showed a mortality rate of 12% (n  44). The
unctional outcome assessment revealed a median mRS of 2
IQR 1 to 4) in the whole stroke population, and 42% (n 
51) of patients had an unfavorable functional outcome
efined as (mRS 2).
R-proANP and severity of stroke on admission according
o the NIHSS. MR-proANP concentrations increased
ith increasing severity of stroke as defined by the NIHSS
Fig. 1). MR-proANP levels in patients with a NIHSS of 0
o 6 points (n 217) were 122.0 pmol/l (IQR 73.4 to 203.5
mol/l), in patients with a NIHSS of 7 to 15 points (n 
0) 168.5 pmol/l (IQR 100.0 to 286.0 pmol/l), and in
atients with a NIHSS 15 points (n  55) 251.5 pmol/l
IQR 129.0 to 372.5 pmol/l) (p  0.0001).
R-proANP and death within 90 days. MR-proANP
evels on admission in the 44 patients who subsequently
ied were about 3-fold increased as compared with survivors
345.0 pmol/l [IQR 232.0 to 465.0 pmol/l] vs. 130.5 pmol/l
IQR 78.2 to 216.5 pmol/l]; p  0.001) (Fig. 2A). Univar-
ate analysis identified MR-proANP concentrations, age,
resence of TACS and POCS, history of heart failure,
oronary artery disease, renal insufficiency, small vessel
isease, and the NIHSS as predictors for death (Table 2).
hereby, the unadjusted OR of log-transformed MR-
roANP was 128.7 (95% CI: 29.7 to 557.1), and for
R-proANP quartiles, it was 4.7 (95% CI: 2.8 to 8.0).
fter combining MR-proANP in bivariate logistic re-
ression analysis with each predictor alone, it remained
n independent predictor. In addition, multivariate anal-
sis restricted to the 4 main predictors, age, the NIHSS,
nd TACS, MR-proANP remained an independent pre-
ictor for mortality with an adjusted OR of 61.01 (95%
I: 9.87 to 377.93); similarly after adjustment for age,
he NIHSS, and heart failure, the adjusted OR was 62.83
95% CI: 9.60 to 411.28) (Table 3). ROCs demonstrated
discriminatory accuracy (AUC) to predict mortality for
R-proANP of 0.86 (95% CI: 0.82 to 0.86), which was
n the range of the NIHSS (AUC: 0.85 [95% CI: 0.78 to
.91]) and copeptin (AUC: 0.82 [95% CI: 0.76 to 0.89]).
R-proANP had a better predictive value as compared
ith CRP (AUC: 0.70 [95% CI: 0.60 to 0.70]; p  0.05)
nd glucose (AUC: 0.57 [95% CI: 0.47 to 0.66]; p 
.01). The combination of MR-proANP and the NIHSS
n a combined logistic model had a significantly higher
iscriminatory accuracy (AUC: 0.92 [95% CI: 0.88 to
.96]) than the AUC of the NIHSS or MR-proANP
lone (p  0.01 and p  0.01, respectively) (Fig. 3). Also,
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roved the discriminatory accuracy of copeptin alone (AUC:
.89 [95% CI: 0.84 to 0.93]; p  0.04). Adding copeptin to
he logistic model of MR-proANP and the NIHSS did not
urther improve the model’s discriminatory ability and
evealed an AUC of 0.92 (95% CI: 0.88 to 0.96).
The time to death in the 90-day follow-up was analyzed
aseline CharacteristicsTable 1 Baseline Characteristics
All
n 359
Demographic data
Age, yrs 75 (63–83)
Female sex 41% (149)
Stroke severity, NIHSS 5 (2–10)
Laboratory findings
MR-proANP, pmol/l† 141.5 (84.1–237.8)
Glucose level, mmol/l 6.1 (5.5–7.4)
C-reactive protein, mmol/l 3.6 (3.0–9.9)
Creatinine, mol/l 76.0 (63.0–89.0)
Vital parameters on admission
Arterial pressure, mm Hg systolic 160 (140–180)
Arterial pressure mm Hg diastolic 90 (80–100)
Body temperature, °C 37.0 (36.5–37.4)
Stroke etiology‡
Small vessel occlusive 15% (55)
Large vessel occlusive 18% (65)
Cardioembolic 37% (131)
Other 4% (16)
Unknown 26% (92)
Stroke syndrome
TACS 11% (41)
PACS 45% (162)
LACS 21% (74)
POCS 23% (83)
Comorbidities
Charlson Index 1 (0–2)
Hypertension 77% (275)
Atrial fibrillation 21% (75)
Heart failure 15% (54)
Renal insufficiency 11% (39)
Smoking history 35% (124)
Hypercholesterolemia 26% (93)
Diabetes mellitus 20% (71)
Coronary heart disease 25% (91)
Prior stroke 25% (88)
Therapies
Antihypertensive (prior to admission) 59% (213)
ASA (prior to admission) 37% (133)
Clopidogrel (prior to admission) 5% (18)
Anticoagulant (prior to admission) 11% (38)
Statins (prior to admission) 22% (78)
Thrombolysis (on admission) 16% (59)
alues are median (interquartile range) or % (n). *p values were assessed using the Mann-Whitney
nd because of rounding, percentages may not sum to 1. Bold values indicate statistical significa
ASA  acetyl salicylic acid; IQR  interquartile range; LACS  lacunar syndrome; mRS modifi
yndrome; POCS  posterior circulation syndrome; TACS  total anterior circulation syndrome.sing Kaplan-Meier survival curves based on MR-proANP 1uartiles. As demonstrated in Figure 4, patients in higher
R-proANP quartiles had an increase in the risk of
ortality.
R-proANP and functional outcome of stroke patients
ithin 90 days. MR-proANP levels in patients with an
nfavorable outcome were about 2-fold higher compared
ith patients with a favorable outcome (213.0 pmol/l [IQR
Favorable Outcome
(mRS 0–2)
Unfavorable Outcome
(mRS 3–6) p Value*
208 151
71 (59–80) 80 (71–86) 0.001
35% (73) 49% (76) 0.01
4 (2–6) 8 (4–17) 0.001
119.0 (72.8–187.0) 213.0 (119.0–332.0) 0.0001
6.0 (5.3–7.2) 6.3 (5.6–7.7) 0.05
3.0 (3.0–6.5) 4.90 (3.0–19.9) 0.001
76.0 (63.5–89.0) 76.0 (62.5–91.0) NS
162 (143–180) 159 (132–180) NS
91 (81–102) 90 (79–98) NS
37.0 (36.7–37.5) 37 (36.4–37.4) NS
18% (38) 11% (17) NS
18% (38) 18% (27) NS
36% (75) 37% (56) NS
5% (11) 3% (5) NS
22% (46) 30% (46) NS
5% (11) 20% (30) 0.0001
44% (92) 47% (69) NS
23% (47) 18% (27) NS
28% (58) 16% (24) 0.01
0 (0–2) 1 (0–2) <0.0001
73% (152) 81% (123) <0.05
16% (34) 27% (41) <0.05
10% (21) 21% (33) <0.05
7% (14) 17% (25) <0.05
38% (79) 30% (45) NS
28% (58) 23% (35) NS
19% (39) 21% (32) NS
23% (48) 28% (43) NS
23% (48) 26% (40) NS
57% (119) 62% (94) NS
36% (74) 39% (59) NS
3% (7) 7% (11) NS
9% (18) 13% (20) NS
23% (47) 21% (31) NS
17% (36) 15% (23) NS
9 patients had missing values for MR-proANP; ‡some patients had 2 etiologies at the same time,
kin Scale; NIHSS  National Institutes of Health Stroke Scale; PACS  partial anterior circulationU test; †
nce.19.0 to 333.0 pmol/l] vs. 119.0 pmol/l [IQR 72.8 to 187.0
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egression analysis, we calculated the predictive value of
R-proANP as compared with the NIHSS and other risk
actors (Table 2). With an unadjusted OR of 10.06 (95%
I: 4.71 to 21.52), for log-transformed MR-proANP levels
nd 1.9 (95% CI: 1.6 to 2.4) for MR-proANP quartiles,
R-proANP was a strong predictor of outcome. Compar-
ng MR-proANP with each significant outcome predictors
n a bivariate regression model, MR-proANP remained an
ndependent predictor (adjustment for the NIHSS revealed
n OR of 5.78 [95% CI: 2.60 to 12.97; p  0.001], for age
n OR of 4.88 [95% CI: 2.08 to 11.46; p  0.001], for
emale sex an OR of 9.30 [95% CI: 4.33 to 19.97; p 
.001], for heart failure an OR of 9.07 [95% CI: 4.10 to
0.05; p 0.001], for AF an OR of 10.08 [95% CI: 4.45 to
2.87; p  0.001], for renal insufficiency an OR of 7.73
95% CI: 3.44 to 17.35; p 0.001], for CRP an OR of 6.47
95% CI: 2.82 to 14.83; p  0.001], for the Charlson Index
n OR of 8.41 [95% CI: 3.84 to 18.41], and for the presence
f TACS an OR of 9.34 [95% CI: 4.28 to 20.34; p 
.001]). When combining all significant predictors in a
ultivariate model, only age, the Charlson score, and the
IHSS remained independent predictors for functional
utcome.
With an AUC of 0.70 (95% CI: 0.65 to 0.75) to predict
unctional outcome, MR-proANP had a significantly
igher prognostic discriminatory capacity as compared with
ACS and sex, and was within the range of copeptin, the
IHSS, and age (Table 4). In addition, MR-proANP
ended to improve the NIHSS with an AUC of the
ombined model of 0.79 (95% CI: 0.74 to 0.83; p  0.05).
R-proANP in different stroke etiologies. When divid-
ng patients into 4 subgroups based on stroke etiology, 18%
n  65) of patients were allocated to the large artery
therosclerosis group, 36% (n 131) to the cardioembolism
CE) group, 15% (n  55) to the small vessel occlusion
Figure 1 MR-proANP Levels and Stroke Severity
According to the NIHSS
All data are medians and interquartile range (IQR) with dot plots representing
all values. The p value refers to a Kruskal-Wallis 1-way analysis of variance.
MR-proANP  midregional pro-atrial natriuretic peptide; NIHSS  National Insti-
tutes of Health Stroke Scale.roup, 4% (n  16) to the group of other etiologies (e.g.,issection), and 26% (n  92) to the group with undeter-
ined etiology. MR-proANP levels were highest in pa-
ients with CE etiology (206 pmol/l [IQR 119 to 326
mol/l]), significantly higher as compared with other etiol-
gies (124 pmol/l [IQR 73 to 207 pmol/l]; p  0.0001).
ogistic regression analysis revealed that MR-proANP was
ignificantly associated with CE etiology (unadjusted OR of
.1 [95% CI: 2.6 to 19.4]), independent of history of
hronic heart failure (adjusted OR: 6.0 [95% CI: 2.3 to
3.9]) and atrial fibrillation (adjusted OR: 14.8 [95% CI:
.2 to 6.1]) and hypertension (OR: 1.5 [95% CI: 0.80 to
.91]). ROC analysis showed an AUC of 0.68 (95% CI:
.62 to 0.74) for cardioembolic etiology. The optimal
iomarker cutoff point for discriminating the presence or
bsence of a cardioembolic source was determined to be
180 pg/ml with a specificity of 60.3% (95% CI: 51.2 to
8.9), sensitivity of 71% (95% CI: 64.6 to 76.8), a positive
ikelihood ratio of 2.0, and a negative likelihood ratio of 0.6.
Figure 2 Log MR-proANP Levels
(A) Log MR-proANP levels in survivors and nonsurvivors of stroke. (B) Log MR-
proANP levels in stroke patients with favorable and unfavorable functional out-
come. All data are medians and IQR, with dot plots representing all values. The
p value refers to a Mann-Whitney U test. Abbreviations as in Table 1.
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osis of CE etiology by already known clinical information,
e calculated logistic models based on clinical information
age, known heart failure, and known AF on admission) and
ombined models based on clinical information plus MR-
roANP concentrations. The model including MR-
roANP (AUC: 0.81 [95% CI: 0.77 to 0.86]) was signifi-
antly better than the model based on clinical information
lone (AUC: 0.76 [95% CI: 0.71 to 0.81]; p  0.001).
R-proANP levels in the subgroup of patients with
eart failure or AF. In 54 (15%) patients with known
hronic heart failure on admission, MR-proANP levels
ere higher as compared with patients without chronic
eart failure (271 pmol/l [IQR 162.5 to 383.8] vs. 132.0
mol/l (IQR 78.1 to 216.6]; p  0.001). MR-proANP
emained a significant predictor for both mortality and
nivariate AnalysesTable 2 Univariate Analyses
Mortality
Odds Ratio R2 95% CI
Laboratory parameters
MR-proANP* 128.31 0.25 29.71–554.22
C-reactive protein 1.10 0.03 0.99–1.21
Creatinine 1.00 0.0006 0.99–1.01
Demographic data
Age 1.09 0.12 1.05–1.14
Female sex 1.35 0.003 0.72–2.54
Stroke severity, NIHSS 1.20 0.28 1.14–1.25
Comorbidities
Charlson Index 1.16 0.008 0.96–1.40
Heart failure 2.44 0.02 1.16–5.10
Atrial fibrillation 3.16 0.001 0.92–6.15
Coronary heart disease 2.07 0.017 1.07–4.00
Renal insufficiency 3.64 0.046 1.65–8.04
Stroke syndrome
TACS 4.44 0.10 2.15–9.19
PACS 1.12 0.0001 0.74–1.69
LACS 0.75 0.02 0.44–1.26
POCS 0.49 0.006 0.29–0.83
Stroke etiology
Small vessel occlusive 0.11 0.03 0.02–0.84
Large vessel occlusive 0.55 0.006 0.21–1.45
Cardioembolic 1.54 0.007 0.82–2.92
Other 0.47 0.002 0.06–3.64
Unknown 1.96 0.01 1.02–3.79
values in bold indicate statistical significance. *Note that the odds ratio corresponds to a unit
ransformation of MR-proANP (thus a log-transformed increase of 1 corresponds to a MR-proANP
ultivariate Analysis for MortalityTable 3 Multivariate Analysis for Mortality
Predictors Odds Ratio 95% CI p Value
MR-proANP 62.83 9.60–411.28 <0.001
Age 1.04 0.99–1.09 0.07
Stroke severity, NIHSS 1.19 1.12–1.26 <0.001
Chronic heart failure 0.76 0.26–2.23 0.60values in bold indicate statistical significance; p values in italics indicate nonsignificance.
Abbreviations as in Tables 1 and 2.unctional outcome after adjustment for heart failure with
Rs of 148.83 (95% CI: 32.16 to 688.67) and 9.07 (95%
I: 4.10 to 20.05), respectively. In addition, ROC analysis
howed a similar predictive value of MR-proANP for both
Figure 3 ROC Area to Predict Mortality
Area under the receiver-operating characteristics curve (ROC) of the NIHSS and
MR-proANP, and the combined AUC. The combined model (AUC of the NIHSS
and AUC of MR-proANP) was more accurate to discriminate survivors from non-
survivors as compared with the clinical score (NIHSS) or the biomarker (MR-
proANP) alone (p  0.01 and p  0.01, respectively). Abbreviations as in
Figure 1.
Functional Outcome
p Value Odds Ratio R2 95% CI p Value
<0.0001 10.07 0.09 4.71–21.52 <0.0001
0.05 1.01 0.02 1.00–1.02 0.01
0.68 1.00 0.0006 0.99–1.00 0.59
<0.0001 1.06 0.09 1.04–1.08 <0.0001
0.93 1.78 0.01 1.17–2.74 0.01
<0.0001 1.16 0.15 1.12–1.21 <0.0001
0.13 1.34 0.03 1.15–1.56 <0.0001
0.02 2.49 0.003 1.38–4.51 0.003
0.09 1.91 0.01 1.14–3.19 0.01
0.03 1.33 0.003 0.82–2.14 0.25
0.001 2.92 0.02 1.46–5.83 0.002
<0.0001 6.67 0.05 3.39–13.99 <0.0001
0.74 0.81 0.0002 0.41–1.54 0.53
0.28 0.35 0.0001 0.12–1.02 0.54
0.01 0.50 0.01 0.20–1.23 0.20
0.03 0.58 0.007 0.30–1.05 0.07
0.23 0.97 0.00001 0.56–1.68 0.93
0.43 1.05 0.0001 0.68–1.62 0.84
0.46 0.61 0.001 0.21–1.80 0.37
0.05 1.54 0.007 0.96–2.49 0.08
e in the explanatory variable; for MR-proANP this corresponds to an increase per unit of the log
e of 10 pmol/l).Bold values indicate statistical significance.
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ot shown).
Similarly, in 75 (21%) patients with AF, MR proANP
evels were higher (258.5 pmol/l [IQR 181.8 to 380.0
mol/l]) as compared with patients without AF (123.5
mol/l [IQR 74.2 to 213.0 pmol/l]; p  0.001). Again,
R-proANP remained a significant predictor for both
utcomes after adjustment for AF. ROC analysis showed a
imilar predictive value of MR-proANP for both outcomes
n patients with and without AF (data not shown).
iscussion
R-proANP levels on admission were increased in stroke
atients, with particularly prominently elevated levels in
atients with cardioembolic strokes. MR-proANP proved
o accurately predict 90-day mortality and functional out-
ome, independent of other comorbidities such as chronic
eart failure and AF, age, and clinical scores. Importantly,
Figure 4 Kaplan-Meier Survival Curves
Estimates by midregional pro-atrial natriuretic peptide (MR-proANP) quartiles and n
OC Analysis of Functional OutcomeTable 4 ROC Analysis of Functional Outcome
Parameter AUC 95% CI p Value*
MR-proANP 0.71 0.65–0.75
Copeptin 0.73 0.67–0.78 0.62
NIHSS 0.75 0.70–0.80 0.21
Age 0.70 0.65–0.75 0.88
Charlson score 0.63 0.58–0.69 0.06
Sex 0.58 0.52–0.63 0.002
Combined score (Copeptin and MR-proANP) 0.73 0.68–0.80 0.78
Combined score (NIHSS and MR-proANP) 0.79 0.74–0.83 0.016
p values indicate significance of area under the curve (AUC) between predictors and MR-proANP.d
values in bold indicate statistical significance.
ROC  receiver-operating characteristic curve; other abbreviations as in Tables 1 and 2.R-proANP improved the prognostic value of the NIHSS.
o our knowledge, this is the first prospective study evalu-
ting MR-proANP levels in a large cohort of stroke
atients.
Elevated concentrations of natriuretic peptides, especially
NP, have been shown to be of prognostic value in patients
ith congestive heart failure and myocardial ischemia (as-
essed by electrocardiographic changes) (18,23,24). Re-
ently, MR-proANP levels were also evaluated in patients
ith heart failure showing comparable prognostic capabili-
ies to BNP values with respect to 1-year all-cause mortality
25). Hence, higher natriuretic peptide levels reflect a
reater degree of hemodynamic dysfunction and explain the
ncreased mortality in patients with acute cardiac disease. A
ole of natriuretic peptides in the hemodynamic regulation
as also been shown during the acute phase of ischemic
troke (7,26–28). Clinical studies have revealed elevated
evels of natriuretic peptides in the acute phase of ischemic
troke (8,28–30). One study (8) reported elevated levels of
NP and ANP in 51 ischemic stroke patients compared
ith healthy controls and higher levels of natriuretic pep-
ides in patients who died as compared with those who
urvived. BNP and its N-terminal peptide (NT-proBNP)
as been demonstrated to be excellent markers for vas-
ular mortality and re-events in stroke (6) although
T-proBNP levels on admission were not significantly
ssociated with functional outcome within 3 months (30)
f adjusted for vascular risk factors in another study.
strada et al. (7) investigated ANP concentrations in 37
atients with acute ischemic stroke. Compared with
ealthy controls, concentration of ANP increased imme-
s at risk. Note that in 9 patients, we had missing values for MR-proANP.umberiately after stroke and remained elevated for 7 days. We
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n the independent predictive value concerning mortality
s well as functional outcome after an acute ischemic
troke.
The relation of natriuretic peptides and stroke prognosis
eems not to be monocausal and is complex. First, it has
een demonstrated that a higher level of NT-proBNP in
troke patients is associated with increased sympathetic
ctivation. Sympathetic activation by itself is a prognostic
eterminant after an acute thromboembolic stroke (31,32).
econd, previous studies have shown that heart failure is
ssociated with dependency after stroke (27) and that it is an
ndependent predictor for mortality after first cerebral in-
arction (33–35).
In our study, unadjusted and adjusted logistic regression
nalysis revealed that levels of MR-proANP were predictors
or 90-day mortality and functional outcome, independently
f the presence of heart failure or AF. The pathophysiolog-
cal mechanism explaining this independent predictive value
f MR-proANP observed in our study remains to be
larified. It may be hypothesized that high MR-proANP
oncentrations indicate the presence of a profound neuro-
ormonal dysfunction, and thus a worse outcome. Further-
ore, increased MR-proANP levels might mirror, not only
anifest heart failure, but also a beginning cardiac pathol-
gy (e.g., subclinical heart failure) in which intracardial
hrombus development might be more likely. This would
xplain the additional diagnostic value of MR-proANP
evels to differentiate CE etiologies from others. It is
ssential to identify the CE etiology in stroke because
ecurrent stroke occurs within 2 weeks in up to 12% of
atients who initially experience embolic stroke from car-
iac sources (36). AF might be no longer present when
atients are examined by 24-h electrocardiography moni-
oring. Thus, anticoagulant therapy might be delayed even
hen the neurologist suspects an embolic origin due to
istinct patterns of lesions. Using biomarkers may be a
easonable strategy to improve the identification of cardio-
mbolic stroke already in the acute phase, thus rapidly point
o need of other diagnostic tests and accelerating the start of
ptimal secondary prevention (26).
Other known mediators involved in the ischemic cascade
re markers for neuronal cell death, such as protein S-100
37), inflammation markers, such as interleukin-6 (38), or
arkers for oxidative stress and blood-brain barrier disrup-
ion, such as matrix metalloproteinase-9 (39,40). Although
hese biomarkers reliably mirror the initial stroke severity
NIHSS and lesion size) and some even bear an association
ith outcome, they were not able to independently predict
unctional outcome and death within 3 months as well as to
mprove the NIHSS. To our knowledge, only 1 circulation
iomarker, copeptin, the c-terminal part of the AVP pro-
ormone, was able to significantly improve prediction of
linical outcome after stroke for death and functional
utcome (19). Copeptin is released in an equimolar ratio to
VP and is more stable in the circulation and easier toetermine as AVP (41). Interestingly, MR-proANP seems
o be a better predictor for mortality, whereas copeptin had
higher prognostic accuracy to predict functional outcome.
ne reason for the absence of a “unique” biomarker pre-
minently mirroring all aspects of prognosis might be that
he complexity of brain ischemia and recovery capacities is
ess amenable to the use of a single biochemical marker. In
he difficult task of outcome prediction, it seems, therefore,
easonable to rely on several parameters, each mirroring
ifferent pathophysiological aspects. The approach of using
multiple biomarker panel has already been well established
n the clinical setting of patients with cardiovascular disease
6,42). A model combining biomarkers and clinical param-
ters might also be the most promising approach to predict
utcome in stroke patients.
tudy limitations. We are aware of the following limita-
ions. First, our study is a single-center study and should be
xternally validated in a large cohort of patients. Second, we
id not directly compare the prognostic value of MR-
roANP with other natriuretic peptides, especially B-type
atriuretic peptides. However, this study shows promising
ata for a further multicenter trial including MR-proANP
n a prognostic biomarker panel.
onclusions
he present study shows that MR-proANP is a new,
aluable marker for the prognosis in patients with ischemic
troke. It also seems to act as a diagnostic marker by
ifferentiating patients with a CE etiology of stroke from
ther etiologies, especially when combining it with clinical
nformation. Early risk assessment in acute ischemic stroke
ay allow for better and earlier intervention and improved
are strategies to effectively change the dismal natural
istory of stroke.
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